Highlights
- Natco Pharma shares rose 1.26% during Thursday's trading session on the NSE.
- The company reported consolidated net profit of INR 26,900 lakh for March 2026 quarter.
- The stock remains higher on both year-to-date and one-year return basis.
Natco Pharma Limited (NSE:NATCOPHARM) ended the trading session on June 25, 2026, at INR 904.90, up INR 11.30 or 1.26% from the previous close. The stock's official closing price stood at INR 903.70, compared with the previous close of INR 893.60.
The stock opened at INR 898.80 and touched an intraday high of INR 918.20 before slipping slightly to close near the day's range. The intraday low stood at INR 898.00, while the volume weighted average price (VWAP) was INR 908.98.
Trading Activity and Market Capitalisation
Natco Pharma recorded traded volume of 8.08 lakh shares during the session, with a traded value of INR 73.49 crore.
The company's total market capitalisation stood at INR 16,207.65 crore, while the free-float market capitalisation was INR 8,094.99 crore. The stock reported an impact cost of 0.03%, and 41.05% of the traded quantity was marked for delivery.
Natco Pharma is listed in the NIFTY Smallcap 100 index and continues to trade in the EQ series.
Stock Performance Across Timeframes
Natco Pharma has delivered mixed returns across different investment periods. Over the past week, the stock gained 1.79%, outperforming the NIFTY 500, which declined 0.13%. During the past month, the shares fell 23.70%, while the benchmark index gained 0.95%.
On a year-to-date basis, Natco Pharma has advanced 1.88%, compared with a 3.33% decline in the NIFTY 500. The stock has gained 3.87% over the past year. However, over the last three years, it has returned 30.12%, while the five-year return stands at negative 17.44%. The stock touched its 52-week high of INR 1,226.80 on May 12, 2026, and its 52-week low of INR 789.00 on September 30, 2025.
March 2026 Financial Performance
For the quarter ended March 31, 2026, Natco Pharma reported audited consolidated total income of INR 81,690 lakh. Consolidated profit before tax stood at INR 14,410 lakh, while consolidated net profit came in at INR 26,900 lakh. Earnings per share (EPS) for the quarter was INR 14.96.
On a standalone basis, total income stood at INR 68,170 lakh. Standalone profit before tax was INR 11,000 lakh, while net profit was INR 20,960 lakh. Standalone earnings per share came in at INR 11.70.
Valuation Snapshot
Natco Pharma operates in the pharmaceuticals industry and has been listed on the National Stock Exchange since December 27, 1995.
According to exchange data, the stock is trading at a price-to-earnings (P/E) ratio of 11.80, indicating its current market valuation based on reported earnings.
Key Risks
- Regulatory actions may affect pharmaceutical product approvals and sales.
- Pricing pressure could impact revenue and profit margins.
- Product concentration may influence financial performance.
- Currency fluctuations may affect export earnings and profitability.
Summary
Natco Pharma shares gained 1.26% on June 25, 2026, even as the stock remained under pressure over the past month. The company reported consolidated net profit of INR 26,900 lakh for the March 2026 quarter. Despite recent volatility, the stock has posted positive returns on both a year-to-date and one-year basis while trading at a P/E ratio of 11.80.
FAQs
Q: What was Natco Pharma's share price on June 25, 2026?
A: Natco Pharma ended the trading session at INR 904.90, while the official closing price was INR 903.70.
Q: What were Natco Pharma's March 2026 quarterly financial results?
A: The company reported consolidated total income of INR 81,690 lakh and consolidated net profit of INR 26,900 lakh.
Q: How has Natco Pharma stock performed in 2026?
A: The stock has gained 1.88% on a year-to-date basis despite declining 23.70% over the past month.